Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2020 07:00 ET | Quelle: Incysus Therapeutics, Inc.

INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
27. Februar 2020 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma

NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
07. Februar 2020 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at the 2020 BIO CEO & Investor Conference

NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
29. Januar 2020 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics Announces Issuance of Foundational U.S. Patent Covering Use of Drug Resistant Immunotherapy (DRI) Technology for the Treatment of Cancer

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
09. Januar 2020 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at Biotech Showcase 2020

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
26. November 2019 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Participate in Evercore ISI HealthCONx Conference

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
21. November 2019 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
07. November 2019 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at the New York Oncology Investor Conference

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
22. Oktober 2019 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at the 2019 Bio Investor Forum

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
10. September 2019 07:00 ET | Quelle: Incysus Therapeutics, Inc.

Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit

NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...

Vorherige Seite